Compositions and methods for modulating lymphocyte activity
CA 2489803 A1 · Owner: Zang, Xingxing · Inventors: Murphy, Kenneth M.; Yang, Jianfei; Murphy, Theresa L.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a novel lymphocyte inhibitory receptor termed BTLA which is expressed on both T and B cells and identifies B7 family member , B7x as interacting with BTLA to attenuate lymphocyte activity. Methods and compositions for modulating BTLA-mediated negative signaling and interfering with the interaction of BTLA and B7x for therapeutic diagnostic and research , purposes are also provided.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed June 20, 2003. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended June 20, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by June 20, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.